Synonyms
Definition
Is an antiangiogenesis agent developed by Regeneron and the Sanofi-Aventis Group; is a fusion protein specifically designed to bind as a soluble decoy receptor all forms of Vascular Endothelial Growth Factor-A (VEGF-A). VEGF-A is required for the growth of new blood vessels that are needed for tumors to grow and is a potent regulator of vascular permeability and leakage. Disruption of the binding of VEGFs to their cell receptors may result in the inhibition of tumor angiogenesis, metastasis, and ultimately lead to tumor regression. In addition, Aflibercept binds Placenta Growth Factor (PLGF), which has also been implicated in tumor angiogenesis. Breast Cancer Targeted Therapy
This is a preview of subscription content, log in via an institution to check access.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer-Verlag Berlin Heidelberg
About this entry
Cite this entry
Schwab, M. (2014). Aflibercept. In: Schwab, M. (eds) Encyclopedia of Cancer. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-27841-9_6691-2
Download citation
DOI: https://doi.org/10.1007/978-3-642-27841-9_6691-2
Received:
Accepted:
Published:
Publisher Name: Springer, Berlin, Heidelberg
Online ISBN: 978-3-642-27841-9
eBook Packages: Springer Reference Biomedicine and Life SciencesReference Module Biomedical and Life Sciences